(Q35019658)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

review article

1 reference

title

Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Angelo Di Leo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

author name string

Martine J Piccart

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

published in

Cancer Treatment Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

page(s)

275-290

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

15 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Late mortality from pT1N0M0 breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Predicting recurrence in axillary-node negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Long-term followup of breast cancer patients: the 30-year report

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Cancer of the breast: Size of neoplasm and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

A prognostic index in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Confirmation of a prognostic index in primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

The Nottingham prognostic index in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Predicting the clinical status of human breast cancer by using gene expression profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Leukemia after therapy with alkylating agents for childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

Adjuvant chemotherapy for breast cancer: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900091-9

7 January 2021

10.1016/S0305-7372(02)00091-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12470979%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference